The Influence of Plasma and Aqueous Cytokine Concentrations on the Efficacy of Intravitreal Ranibizumab for the Treatment of Diabetic Macular Oedema.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Jan 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacodynamics
- Acronyms DME Cytokine
- 02 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Sep 2015 New trial record